It is not unusual for drugs to fail Phase 3 pivotal studies after showing success in Phase 2 studies. In fact, it is the norm rather than the exception. And this reality is not limited to experimental drugs … almost every major anti-cancer drug on the market today has failed at least one pivotal study [...]
Comment 27 June
The wait is over, and no doubt everyone feels as gutted as I do. But before we slit our collective wrists, I urge some perspective. Novogen is, and has always been, a lot more than just PXD and OVATURE. That has been the focus of market attention, and the failure of the trial is what [...]
A number of correspondents have asked generously about my health. It isn’t something that I have been anxious to broadcast, in part because it is a private matter, and in part because I am sure others have more to complain about than me. But I have decided to talk about it now in the hope [...]
With the MSHL annual shareholders meeting out of the way, I have a few comments. I also note some comments on the Yahoo message board following the recent presentation which I will follow up on here. 1. On the departure of Chris Naughton, as I have said previously, I have no inside knowledge on the background to [...]
Two recent reports purport to show that PXD modifies the activity of both normal lymphocytes and leukaemic cells, with the suggestion that it might have therapeutic potential in the treatment of certain blood-related disorders including leukaemia and certain autoimmune diseases. The first report is as follows. Phenoxodiol, an anticancer isoflavene, induces immunomodulatory effects in vitro [...]
From the outset, prostate cancer has been a highly promising target for phenoxodiol (PXD), based on a range of mechanisms of action that have particular application in this form of cancer. The following is divided into four parts. The first part is a background look at prostate cancer, in particular those aspects of the disease [...]
The 14 April 2009 announcement concerning the halting of recruitment in the OVATURE study clearly is of considerable significance for the immediate future of the Company. Despite the fact that the Company’s future is based on a substantial technology platform and is a whole lot more than one drug or one clinical trial, there is [...]
Triphendiol is the second anti-cancer drug from the Novogen isoflavonoid drug pipeline to enter the clinic. Triphendiol (previously known as NV-196) is a modification of the phenoxodiol skeleton. Phenoxodiol Triphendiol Being closely related structurally, the two drugs not surprisingly display many features in common. Like phenoxodiol, triphendiol displays the following characteristics: it is orally available [...]